financetom
Business
financetom
/
Business
/
Rivalry Closes C$1.5 Million Private Placement; Completes Debt Restructuring With Senior Lender
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rivalry Closes C$1.5 Million Private Placement; Completes Debt Restructuring With Senior Lender
Oct 24, 2025 2:25 PM

04:55 PM EDT, 10/24/2025 (MT Newswires) -- Rivalry (RVLY.V), after trade Friday, said it has closed the third tranche of its private placement.

The company said it raised about C$1.5 million by issuing nearly 30 million units at C$0.05 each. Each warrant is exercisable into one SV share at a price of C$0.10 per warrant share until October 8, 2027.

Proceeds will be used for corporate development and general working capital. Rivalry may complete a final tranche of the placement by Nov. 15, the company added.

The company also said it completed its debt restructuring with its senior lender. Per the agreement, Rivalry settled about C$12.5 million of its debt by issuing about 250.5 million shares and warrants at the offering price.

The remaining C$8.48 million of debt was converted into a secured debenture that can be converted into shares at C$0.10 per share, with no interest payable until December 2026 and a maturity date of Nov. 14, 2028, according to the statement.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hims & Hers Health Insider Sold Shares Worth $4,200,307, According to a Recent SEC Filing
Hims & Hers Health Insider Sold Shares Worth $4,200,307, According to a Recent SEC Filing
May 6, 2024
03:23 AM EDT, 05/06/2024 (MT Newswires) -- Andrew Dudum, 10% Owner, Director, Chief Executive Officer, on May 01, 2024, sold 333,332 shares in Hims & Hers Health ( HIMS ) for $4,200,307. Following the Form 4 filing with the SEC, Dudum has control over a total of 11,241,475 shares of the company, with 11,241,475 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1773751/000177375124000125/xslF345X03/wk-form4_1714775923.xml Price:...
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing
May 6, 2024
03:21 AM EDT, 05/06/2024 (MT Newswires) -- Jeremy Bender, Director, Chief Executive Officer, on May 01, 2024, sold 79,211 shares in Day One Biopharmaceuticals ( DAWN ) for $1,415,707. Following the Form 4 filing with the SEC, Bender has control over a total of 1,686,326 shares of the company, with 642,602 shares held directly and 1,043,724 controlled indirectly. SEC Filing:...
Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing
Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing
May 6, 2024
03:20 AM EDT, 05/06/2024 (MT Newswires) -- Noubar Afeyan, Director, on May 01, 2024, sold 15,000 shares in Moderna ( MRNA ) for $1,663,855. Following the Form 4 filing with the SEC, Afeyan has control over a total of 11,692,969 shares of the company, with 2,026,931 shares held directly and 9,666,038 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1682852/000095017024053125/xslF345X03/ownership.xml Price: 125.36, Change: +0.36,...
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing
May 6, 2024
03:22 AM EDT, 05/06/2024 (MT Newswires) -- Charles N York II, Chief Operating and Financial Officer, Secretary, on May 01, 2024, sold 60,461 shares in Day One Biopharmaceuticals ( DAWN ) for $1,081,191. Following the Form 4 filing with the SEC, York has control over a total of 217,293 shares of the company, with 217,293 shares held directly. SEC Filing:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved